These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

113 related items for PubMed ID: 12210411

  • 21. Dynamics of hypervariable region 1 variation in hepatitis C virus infection and correlation with clinical and virological features of liver disease.
    Brambilla S, Bellati G, Asti M, Lisa A, Candusso ME, D'Amico M, Grassi G, Giacca M, Franchini A, Bruno S, Ideo G, Mondelli MU, Silini EM.
    Hepatology; 1998 Jun; 27(6):1678-86. PubMed ID: 9620342
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. The protein kinase-interacting domain in the hepatitis C virus envelope glycoprotein-2 gene is highly conserved in genotype 1-infected patients treated with interferon.
    Polyak SJ, Nousbaum JB, Larson AM, Cotler S, Carithers RL, Gretch DR.
    J Infect Dis; 2000 Aug; 182(2):397-404. PubMed ID: 10915068
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Interferon-alpha and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis.
    Cacoub P, Lidove O, Maisonobe T, Duhaut P, Thibault V, Ghillani P, Myers RP, Leger JM, Servan J, Piette JC.
    Arthritis Rheum; 2002 Dec; 46(12):3317-26. PubMed ID: 12483738
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Interferon treatment for patients with chronic hepatitis C infected with high viral load of genotype 2 virus.
    Nakamura H, Ogawa H, Kuroda T, Yamamoto M, Enomoto H, Kishima Y, Yoshida K, Ito H, Matsuda M, Noguchi S.
    Hepatogastroenterology; 2002 Dec; 49(47):1373-6. PubMed ID: 12239945
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Relationships between TT virus infection and hepatitis C virus response to interferon therapy in doubly infected patients.
    Maggi F, Fornai C, Tempestini E, Andreoli E, Lanini L, Vatteroni ML, Pistello M, Marchi S, Antonelli G, Bendinelli M.
    J Biol Regul Homeost Agents; 2003 Dec; 17(2):176-82. PubMed ID: 14518719
    [Abstract] [Full Text] [Related]

  • 31. Sequential changes of hepatitis C virus antibody profiles during treatment of chronic hepatitis C of genotype 1b: pretreatment antibody response to E2/NS1 correlated sustained response.
    Chu CM, Sheen IS, Liaw YF.
    Infection; 2004 Jun; 32(3):153-6. PubMed ID: 15188075
    [Abstract] [Full Text] [Related]

  • 32. Immune selection and genetic sequence variation in core and envelope regions of hepatitis C virus.
    Christie JM, Chapel H, Chapman RW, Rosenberg WM.
    Hepatology; 1999 Oct; 30(4):1037-44. PubMed ID: 10498657
    [Abstract] [Full Text] [Related]

  • 33. Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.
    Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.
    J Med Virol; 2005 Apr; 75(4):550-8. PubMed ID: 15714492
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Quasispecies heterogeneity within the E1/E2 region as a pretreatment variable during pegylated interferon therapy of chronic hepatitis C virus infection.
    Chambers TJ, Fan X, Droll DA, Hembrador E, Slater T, Nickells MW, Dustin LB, Dibisceglie AM.
    J Virol; 2005 Mar; 79(5):3071-83. PubMed ID: 15709027
    [Abstract] [Full Text] [Related]

  • 37. Hepatitis C virus genetic variability in 52 human immunodeficiency virus-coinfected patients.
    Neau D, Jouvencel AC, Legrand E, Trimoulet P, Galperine T, Chitty I, Ventura M, Le Bail B, Morlat P, Lacut JY, Ragnaud JM, Dupon M, Fleury H, Lafon ME.
    J Med Virol; 2003 Sep; 71(1):41-8. PubMed ID: 12858407
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Dynamics of genome change in the E2/NS1 region of hepatitis C virus in vivo.
    Higashi Y, Kakumu S, Yoshioka K, Wakita T, Mizokami M, Ohba K, Ito Y, Ishikawa T, Takayanagi M, Nagai Y.
    Virology; 1993 Dec; 197(2):659-68. PubMed ID: 8249288
    [Abstract] [Full Text] [Related]

  • 40. Changes in hepatitis C virus (HCV) antibody status in patients with chronic hepatitis C after eradication of HCV infection by interferon therapy.
    Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Kuzuya T, Honda T, Hayashi K, Nakano I, Katano Y, Goto H.
    Clin Infect Dis; 2005 Mar 15; 40(6):e49-54. PubMed ID: 15736006
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.